Welcome to the Cell, Molecular, and Developmental Biology (CMDB) PhD Theme, a part of the Graduate Biomedical Sciences program at the University of Alabama at Birmingham School of Medicine. The CMDB theme is designed to provide maximum flexibility that results in students who are prepared to launch into a career in the emerging biomedical science field. Our graduates have exciting careers in scientific research in both academic and industrial settings; scientific-related writing, business, law, bioterrorism, forensics, administration, and education.
About Us: CMDB is a cross-disciplinary theme at a leading research University in the sunny south, consisting of a diverse group of scientists and physicians who have a collective interest in fundamental processes in cell, molecular, and developmental biology and how alterations in these processes result inhuman diseases and birth defects.
About UAB: We are consistently one of the top 25 NIH funded research institutions in the U.S. and with faculty from over 30 departments across campus there are many opportunities for you in new and exciting areas of biomedical research. And, UAB is a leader in innovative technology such as whole genome sequencing, electron microscopy, mass spectrometry, crystallography, flow cytometry, drug discovery and others.
Contact Us: We are always searching for the brightest and most dedicated students to join our highly competitive CMDB theme and experience firsthand our cutting edge science. This is your personal invitation to explore the many possible opportunities offered by CMDB at UAB. Please explore this web site and apply today!
Professor Anthony Hood will receive special recognition for his work creating the NHabit Bush Hills project during the 2015 Vulcans Community Awards.A University of Alabama at Birmingham professor is being honored at the 2015 Vulcans Community Awards for his work to promote civic pride, leadership and progress within Birmingham’s metro area. Anthony Hood, Ph.D., a management professor in the Collat School of Business, is the recipient of the Game Changer Spear award, for which he will be recognized at a dinner held Thursday, Oct. 8, at The Club. Hood will be honored alongside UAB head football coach Bill Clark, the recipient of the Game Changer Vulcan award. Hood, a Birmingham native who graduated from Ramsay High School, was awarded a Community Health Innovation Award with his wife from UAB’s Center for Clinical and Translational Sciences in 2013. The Hoods used the award to fund their project NHabit Bush Hills, an effort to create...
Telemedicine helps UAB take pulmonary rehabilitation into the home via smartphone technology, in an effort to reduce hospital readmissions from COPD. Harold Ridgeway is a type ‘A’ kind of guy. “I had my first heart attack when I was 50,” recalled the retired businessman. He is the type who often worked 16 hours a day during a career owning steel fabricating plants. He made a good living; but the heart attacks, bypass surgeries and ultimately chronic obstructive pulmonary disease — or COPD — caused by 45 years of smoking, have taken their toll. “I was diagnosed with COPD a few years ago,” said Ridgeway, who is now 76. “I end up in UAB Hospital at least once a year. Something will happen where I can’t breathe.” Most COPD patients experience frequent exacerbations of their disease that may require hospitalization, says Surya Bhatt, M.D., a pulmonologist at the University of Alabama at Birmingham. And about...
UAB researcher reports that brentuximab vedotin may be effective therapy for older patients with Hodgkin Lymphoma who cannot tolerate standard therapy.Andres ForeroA new University of Alabama at Birmingham research study reports that brentuximab vedotin is an effective and safe first course of treatment for older patients with Hodgkin lymphoma that cannot be treated with conventional combination chemotherapy. Results of the study, led by Andres Forero, M.D., professor in the UAB Division of Hematology and Oncology, were published online last month in Blood, the journal of the American Society of Hematology. In 2014, about 9,190 patients were diagnosed with Hodgkin lymphoma in the United States, and up to 20 percent of newly diagnosed Hodgkin Lymphoma patients are 60 years of age or older. While standard chemotherapy can achieve complete remissions and cures in younger patients with Hodgkin lymphoma, the majority of those 60 and older either are ineligible because of other serious medical conditions...